Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Background and Objectives Autologous stem cell transplantation (ASCT) is effective in mantle cell lymphoma (MCL). We investigated whether incorporation of rituximab into the high-dose regimen might further improve the results of ASCT in patients with MCL.Design and Methods In a prospective phase II...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[January, 2007]
|
| In: |
Haematologica, the hematology journal
Year: 2007, Volume: 92, Issue: 1, Pages: 42-49 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.10608 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.10608 Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/4303 
|
| Author Notes: | Peter Dreger, Michael Rieger, Bärbel Seyfarth, Manfred Hensel, Michael Kneba, Anthony D. Ho, Norbert Schmitz, Christiane Pott |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1775900436 | ||
| 003 | DE-627 | ||
| 005 | 20230426125444.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211102s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.10608 |2 doi | |
| 035 | |a (DE-627)1775900436 | ||
| 035 | |a (DE-599)KXP1775900436 | ||
| 035 | |a (OCoLC)1341422373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 245 | 1 | 0 | |a Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma |b effects on molecular response and clinical outcome |c Peter Dreger, Michael Rieger, Bärbel Seyfarth, Manfred Hensel, Michael Kneba, Anthony D. Ho, Norbert Schmitz, Christiane Pott |
| 264 | 1 | |c [January, 2007] | |
| 300 | |b Diagramme | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.11.2021 | ||
| 520 | |a Background and Objectives Autologous stem cell transplantation (ASCT) is effective in mantle cell lymphoma (MCL). We investigated whether incorporation of rituximab into the high-dose regimen might further improve the results of ASCT in patients with MCL.Design and Methods In a prospective phase II study, patients with newly diagnosed MCL were treated with a sequential dose-escalating therapy comprising standard chemotherapy for remission induction, intensive ara-C-containing chemotherapy for mobilization of stem cells, and myeloablative therapy followed by ASCT. The myeloablative regimen consisted of total body irradiation and high-dose cyclophosphamide supplemented with two doses (375 mg/m3) of rituximab. Outcome parameters (toxicity, clinical and molecular response as assessed by allele-specific IGH real-time quantitative polymerase chain reaction (RQ-PCR), event-free survival, and overall survival) were compared with those of 34 historical controls treated identically but without rituximab.Results Thirty-four patients were accrued. Whereas engraftment, toxicity and clinical response were not different from those in controls, event-free survival was significantly increased with rituximab (not reached vs. 43 months; hazard ratio 0.38; p=0.036). This was associated with a trend for a superior molecular response rate in 11 study vs. 10 control patients with a marker available (73% vs. 30%, p=0.086) despite similar levels of lymphoma contamination of the stem cell inocula infused.Interpretation and Conclusions Incorporation of two standard doses of rituximab into the myeloablative regimen might improve outcome of upfront ASCT for MCL, allowing long-term disease control to an extent previously not reached in this disease. | ||
| 700 | 1 | |a Rieger, Michael |e VerfasserIn |0 (DE-588)1050736222 |0 (DE-627)784811342 |0 (DE-576)404987486 |4 aut | |
| 700 | 1 | |a Seyfarth, Bärbel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hensel, Manfred |d 1964- |e VerfasserIn |0 (DE-588)1065849729 |0 (DE-627)816878307 |0 (DE-576)425541908 |4 aut | |
| 700 | 1 | |a Kneba, Michael |d 1950- |e VerfasserIn |0 (DE-588)101170644X |0 (DE-627)659309726 |0 (DE-576)343539187 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pott, Christiane |e VerfasserIn |0 (DE-588)1020732997 |0 (DE-627)691326142 |0 (DE-576)361909322 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica, the hematology journal |d Pavia : Ferrata Storti Foundation, 2005 |g 92(2007), 1 vom: Jan., Seite 42-49 |h Online-Ressource |w (DE-627)48524375X |w (DE-600)2186022-1 |w (DE-576)414771095 |x 1592-8721 |7 nnas |a Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma effects on molecular response and clinical outcome |
| 773 | 1 | 8 | |g volume:92 |g year:2007 |g number:1 |g month:01 |g pages:42-49 |g extent:8 |a Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma effects on molecular response and clinical outcome |
| 856 | 4 | 0 | |u https://doi.org/10.3324/haematol.10608 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://haematologica.org/article/view/4303 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211102 | ||
| 993 | |a Article | ||
| 994 | |a 2007 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1065849729 |a Hensel, Manfred |m 1065849729:Hensel, Manfred |d 910000 |d 910100 |e 910000PH1065849729 |e 910100PH1065849729 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1050736222 |a Rieger, Michael |m 1050736222:Rieger, Michael |d 910000 |d 910100 |e 910000PR1050736222 |e 910100PR1050736222 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1775900436 |e 3998503277 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma","subtitle":"effects on molecular response and clinical outcome","title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma"}],"language":["eng"],"name":{"displayForm":["Peter Dreger, Michael Rieger, Bärbel Seyfarth, Manfred Hensel, Michael Kneba, Anthony D. Ho, Norbert Schmitz, Christiane Pott"]},"origin":[{"dateIssuedDisp":"[January, 2007]","dateIssuedKey":"2007"}],"recId":"1775900436","person":[{"family":"Dreger","display":"Dreger, Peter","given":"Peter","role":"aut"},{"display":"Rieger, Michael","given":"Michael","family":"Rieger","role":"aut"},{"role":"aut","display":"Seyfarth, Bärbel","given":"Bärbel","family":"Seyfarth"},{"role":"aut","display":"Hensel, Manfred","given":"Manfred","family":"Hensel"},{"family":"Kneba","given":"Michael","display":"Kneba, Michael","role":"aut"},{"family":"Ho","display":"Ho, Anthony Dick","given":"Anthony Dick","role":"aut"},{"role":"aut","family":"Schmitz","given":"Norbert","display":"Schmitz, Norbert"},{"family":"Pott","given":"Christiane","display":"Pott, Christiane","role":"aut"}],"note":["Gesehen am 02.11.2021"],"relHost":[{"title":[{"title":"Haematologica, the hematology journal","subtitle":"official organ of the European Hematology Association","title_sort":"Haematologica, the hematology journal"}],"origin":[{"publisher":"Ferrata Storti Foundation","dateIssuedDisp":"2005-2013","dateIssuedKey":"2005","publisherPlace":"Pavia"}],"note":["Gesehen am 27.09.2018"],"id":{"issn":["1592-8721"],"zdb":["2186022-1"],"eki":["48524375X"]},"part":{"issue":"1","extent":"8","pages":"42-49","year":"2007","volume":"92","text":"92(2007), 1 vom: Jan., Seite 42-49"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"disp":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma effects on molecular response and clinical outcomeHaematologica, the hematology journal","recId":"48524375X","pubHistory":["90.2005 - 98.2013"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"id":{"doi":["10.3324/haematol.10608"],"eki":["1775900436"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"noteIll":"Diagramme","extent":"8 S."}]} | ||
| SRT | |a DREGERPETERITUXIMABA2007 | ||